Maryam Zanjirband Zanjirband
Professor Nicola Curtin
Professor John Lunec
| Erratum: Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer (Oncotarget (2017) 8 41 (69779-69796)) | 2024 |
|
Lucy Gentles
Liz Matheson
Dr Nicholas Bown
Alice Bradbury
Maryam Zanjirband Zanjirband
et al. | Characterization and drug sensitivity of a novel human overian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor | 2018 |
|
Maryam Zanjirband Zanjirband
Professor Nicola Curtin
Professor John Lunec
| Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer | 2017 |
|
Maryam Zanjirband Zanjirband
Professor Richard Edmondson
Professor John Lunec
| Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents in combined treatment with cisplatin in ovarian cancer | 2016 |
|
